Used in the treatment of solid tumors, particularly in advanced or metastatic cancers. Targets the macrophage migration inhibitory factor (MIF) pathway by binding to the CD147 receptor (STAB1), helping to activate tumor-associated macrophages and enhance anti-tumor immune responses. Investigated in clinical trials for cancers such as pancreatic, ovarian, and colorectal carcinomas. Shows potential in overcoming immunosuppressive tumor microenvironments, making it a candidate for combination therapies with checkpoint inhibitors. Also explored for its role in promoting immune cell infiltration into tumors.